A synergy of Enamine Chemistry and Bienta Biology: Medicinal Chemistry, Molecular Modeling, High-Throughput Screening, ADME-Tox. Weeks from in silico data set to hits and leads.
All laboratories at Bienta operate according to the standard international quality control practices. Bienta holds a permit from Ukrainian regulatory agencies to provide analytical support for clinical trial PK/bioequivalence studies in humans.
All of our personnel hold M.S. and Ph.D. degrees in Chemistry/Biology and many staff members have years of working experience in various research centers of the US and Europe.
Striving for excellence:
Outsource your research to the largest drug discovery CRO in Ukraine. We build our competitiveness on the integration with the established leader in screening compound libraries and custom chemistry and recruitment of the best local scientists in an emerging Eastern European economy.
Bienta is a trademark for preclinical biology services of Enamine, the world’s largest supplier of drug-like molecules for drug discovery research. Bienta is operating as a Contract Research Organisation (CRO) providing biomolecular screening (HTS) services as well as comprehensive bioanalytical support of drug discovery projects, including in vitro ADMET (absorption, distribution, metabolism, excretion, toxicity) testing as well as pharmacokinetics (PK), toxicity and efficacy studies in animals.
High Throughput Screening & ADME Services
HTS Lab at Bienta is a well-equipped screening facility with a broad range of robotic liquid handling and signal readout technology capabilities as well as the capacity to run both biochemical and cell-based assays in 384-well plate format. Bioanalytical Lab is established to provide all common in vitro ADMET tests as well as analytical support of pharmacokinetics and animal toxicity services.
Discover your molecules with us
News & Events
In September, several Bienta scientisits will be attending international meetings: 4th INTERNATIONAL MASS SPECTROMETRY SCHOOL (IMSS), Barcelona, Spain, September 15-20, 2019: Maria Kliachyna will be presenting a poster: “Application of Tandem Mass Spectrometry to Study Drug Metabolism and Metabolism-Mediated Drug Interaction”. BASEL LIFE 2019, Basel, Switzerland, September 9-12, 2019: Anastasiia Gryniukova will be presenting a poster: “Discovery of MYST1 small-molecule inhibitors as...
2nd International Helmholtz Drug Discovery Conference, Apr 26-27, 2018, at Helmholtz Zentrum München
We are proud to announce that Enamine/Bienta is a Silver Sponsor of the 2nd International Helmholtz Drug Discovery Conference, Apr 26-27, 2018, at Helmholtz Zentrum München. Our poster “Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors” can be accessed here....
Just out of print: an article with the results of IPAB* contest in Japan was published in Nature Scientific Reports. A compound library was originally provided by Enamine Ltd. and contained 2,382,017 of the stock compounds. In this work, BIENTA performed high-throughput screening of the compounds, based on inhibition activity and results. The screening was conducted in three steps consisting of...